KROS vs. ARGX: Which Stock Is the Better Value Option? [Yahoo! Finance]
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: Yahoo! Finance
argenex SE (ARGX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Keros Therapeutics, Inc. has a Zacks Rank of #1 (Strong Buy), while argenex SE has a Zacks Rank of #3 (Hold) right now. This means that KROS's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors. Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels. Our Value category highlights underva
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
- How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Announces Final Results of Tender Offer [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Announces Final Results of Tender OfferGlobeNewswire
- Keros Therapeutics Announces Preliminary Results of Tender OfferGlobeNewswire
KROS
Earnings
- 11/5/25 - Beat
KROS
Sec Filings
- 11/20/25 - Form SC
- 11/19/25 - Form SC
- 11/18/25 - Form SCHEDULE
- KROS's page on the SEC website